Compare CODA & RPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CODA | RPTX |
|---|---|---|
| Founded | 1994 | 2016 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 98.9M | 92.4M |
| IPO Year | N/A | 2020 |
| Metric | CODA | RPTX |
|---|---|---|
| Price | $9.00 | $2.14 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $3.50 |
| AVG Volume (30 Days) | 44.1K | ★ 1.3M |
| Earning Date | 01-28-2026 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 15.09 | N/A |
| EPS | ★ 0.30 | N/A |
| Revenue | ★ $24,347,217.00 | $11,870,000.00 |
| Revenue This Year | $30.82 | N/A |
| Revenue Next Year | $20.84 | $9.55 |
| P/E Ratio | $30.17 | ★ N/A |
| Revenue Growth | ★ 29.34 | N/A |
| 52 Week Low | $5.76 | $0.89 |
| 52 Week High | $10.54 | $4.07 |
| Indicator | CODA | RPTX |
|---|---|---|
| Relative Strength Index (RSI) | 55.10 | 57.57 |
| Support Level | $8.34 | $2.11 |
| Resistance Level | $9.00 | $2.24 |
| Average True Range (ATR) | 0.40 | 0.06 |
| MACD | 0.08 | -0.01 |
| Stochastic Oscillator | 86.99 | 31.03 |
Coda Octopus Group Inc develops underwater technologies and equipment for imaging, mapping defense, and survey applications. The company's operations are organized into two reportable segments: the Products Segment (Marine Technology Business serving the subsea market and PAL, which sells other products (acoustic hydrophones and acoustic materials to a different market); and the Services Segment (Marine Engineering Business). Its geographical segments are the Americas, Europe, Australia/Asia, and the Middle East/Africa. The majority of revenue is derived from the Products segment.
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations.